Current status of urologic oncology clinics in Mexico

Abstract

Background: Most genitourinary (GU) neoplasms have several treatment options should be discussed by a multidisciplinary team. In Mexico, the status of urologic oncology clinics (UOCs) is unknown. Objective: Our aim was to evaluate the current status of UOC, determine the existence of GU-MTB, and define the resource disparities among centers in Mexico. Methods: A cross-sectional study based on an online survey developed by the Genitourinary Mexican Cooperative ResearchGroup in Oncology. Descriptive statistics were used for analysis. Results: Twenty UOCs were identified and were located in 8 of 32 states. Only 50% reported having a multidisciplinary tumor board (MTB). Medical oncology, urology, and radiation oncology participated in 90% of UOCs; nursing, social work, and research staff participation were absent. Ninety percent of MTBs reported discussing all GU neoplasms, one center exclusively discussed kidney cancer cases. Conclusions: There are 20 institutions with these clinics in the country, they are located in only 3 of 32 states. The uneven geographical distribution and the unequal availability of resources reflect the disparity in access to health care services.

Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group

“…In Mexico, the approach to NMIBC care is relatively comprehensive in urban areas but is highly inconsistent across the country due to the uneven distribution of healthcare resources. Most major cities have adequate facilities to follow EAU guidelines, but rural areas often have insufficient access to specialised care, leading to significant deviations from these guidelines [ 17 , 29 ].…”

“…Argentina struggles with production inconsistencies despite having manufacturing facilities, resulting in only moderate availability. In Mexico, vast geographic and economic inequalities exacerbate the shortage, particularly affecting rural areas where adherence to treatment guidelines is low, and patient outcomes vary significantly [ 29 ].…”